罗格列酮结合二甲双胍对多囊卵巢综合征患者胰岛素抵抗指数的影响及临床疗效

目的:探讨罗格列酮与二甲双胍联合给药对多囊卵巢综合征(PCOS)患者胰岛素抵抗指数(HOMA-IR)的变化影响与临床效果的评价。方法:回顾性选取我院收治的PCOS患者127例列为研究样本,按照用药方案差异分为两组,对照组62例采用二甲双胍进行治疗;研究组65例采用罗格列酮联合二甲双胍治疗。观察并比较两组患者治疗前后HOMA-IR、血清性激素水平、排卵率及副反应发生情况。结果:治疗后,研究组HOMA-IR低于对照组,排卵率高于对照组(P0.05);研究组患者血清E2及T水平低于对照组,而FSH及SHBG水平高于对照组(P0.05);两组患者副反应发生率比较,差异无统计学意义(P0.05)。结论:罗格列酮辅助二甲双胍治疗PCOS可显著改善患者HOMA-IR,对性激素平衡有良好作用,副作用较小。

Effect of Rosiglitazone Combined with Metformin on Insulin Resistance Indexes in Patients with Polycystic Ovary Syndrome and Its Clinical Curative Effect

ABSTRACT Objective: To investigate the effects of rosiglitazone and metformin on insulin resistance index (HOMA-IR) in patients with polycystic ovary syndrome (PCOS) and evaluate the clinical effect. Methods: 127 PCOS patients were retrospectively selected and according to the different treatment methods, the patients were divided into two groups. 62 cases in the control group were treated with metformin, and another 65 cases in the study group were treated with rosiglitazone combine metformin. Then the HOMA-IR, serum sex hormone levels, ovulation rate and side effects of the two groups were observed and compared. Results: After the treatment, the HOMA-IR in the study group was significantly lower than that of the control group, while the ovulation rate was significantly higher (P<0.05). The serum levels of E2 and T in the study group were significantly lower than those of the control group, while the FSH and SHBG were higher (P<0.05). There was no statistically significant difference about the side effect rate between the two groups (P>0.05). Conclusion: Rosiglitazone combine metformin can significantly improve the HOMA-IR and balance the serum levels of sex hormones of patients with PCOS, which is effective and safe.